TWI652072B - 使用鹽敏感性乳液系統對人類淚液膜進行高效脂質傳遞 - Google Patents

使用鹽敏感性乳液系統對人類淚液膜進行高效脂質傳遞 Download PDF

Info

Publication number
TWI652072B
TWI652072B TW101146304A TW101146304A TWI652072B TW I652072 B TWI652072 B TW I652072B TW 101146304 A TW101146304 A TW 101146304A TW 101146304 A TW101146304 A TW 101146304A TW I652072 B TWI652072 B TW I652072B
Authority
TW
Taiwan
Prior art keywords
concentration
salt
pharmaceutical composition
low
ophthalmic pharmaceutical
Prior art date
Application number
TW101146304A
Other languages
English (en)
Chinese (zh)
Other versions
TW201325633A (zh
Inventor
彼德A 賽門
Peter A. Simmons
喬瑟夫G 微奇
Joseph G. Vehige
Original Assignee
歐樂根公司
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI652072(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 歐樂根公司, Allergan, Inc. filed Critical 歐樂根公司
Publication of TW201325633A publication Critical patent/TW201325633A/zh
Application granted granted Critical
Publication of TWI652072B publication Critical patent/TWI652072B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW101146304A 2011-12-07 2012-12-07 使用鹽敏感性乳液系統對人類淚液膜進行高效脂質傳遞 TWI652072B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161568089P 2011-12-07 2011-12-07
US61/568,089 2011-12-07
US201261625401P 2012-04-17 2012-04-17
US61/625,401 2012-04-17

Publications (2)

Publication Number Publication Date
TW201325633A TW201325633A (zh) 2013-07-01
TWI652072B true TWI652072B (zh) 2019-03-01

Family

ID=47459152

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101146304A TWI652072B (zh) 2011-12-07 2012-12-07 使用鹽敏感性乳液系統對人類淚液膜進行高效脂質傳遞

Country Status (27)

Country Link
US (2) US20130150324A1 (enExample)
EP (5) EP3981387A1 (enExample)
JP (1) JP6142419B2 (enExample)
KR (1) KR102017922B1 (enExample)
CN (2) CN108969482A (enExample)
AR (1) AR089123A1 (enExample)
AU (2) AU2012347459A1 (enExample)
BR (1) BR112014013820A2 (enExample)
CA (1) CA2858574C (enExample)
CL (1) CL2014001518A1 (enExample)
CO (1) CO6990739A2 (enExample)
DK (2) DK2787969T3 (enExample)
ES (2) ES2797650T3 (enExample)
HU (2) HUE057140T2 (enExample)
IL (1) IL233008A (enExample)
IN (1) IN2014CN04809A (enExample)
MX (1) MX355216B (enExample)
MY (1) MY173378A (enExample)
PH (2) PH12014501296B1 (enExample)
PL (2) PL2787968T3 (enExample)
PT (2) PT2787968T (enExample)
RU (1) RU2014127074A (enExample)
SG (1) SG11201403013VA (enExample)
SI (2) SI2787968T1 (enExample)
TW (1) TWI652072B (enExample)
WO (2) WO2013086449A1 (enExample)
ZA (1) ZA201404228B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
DK3266446T3 (en) 2016-07-07 2019-02-11 Salvat Lab Sa Eye preparation comprising castor oil and medium chain triglyceride
CA3032695C (en) 2016-08-19 2021-11-23 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
BR112020003276A2 (pt) 2017-08-18 2020-09-01 Akrivista, LLC métodos de diagnóstico e tratamento da síndrome do olho seco e composições para tratamento de um olho humano
JP7490570B2 (ja) 2018-04-27 2024-05-27 アラーガン、インコーポレイテッド 抗微生物有効性の増強及び毒性の減少を有する亜塩素酸ナトリウム組成物
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201316984A (zh) 2011-10-06 2013-05-01 Allergan Inc 治療乾眼病的組合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
ATE6466T1 (de) * 1979-10-26 1984-03-15 Smith And Nephew Associated Companies P.L.C. Autoklavierbare emulsionen.
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
ES2038580T3 (es) 1989-08-03 1994-10-16 Eisai Co Ltd Metodo de fotoestabilizacion de soluciones oftalmicas.
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
EP0778021A4 (en) 1994-09-14 1998-06-03 Taisho Pharmaceutical Co Ltd DROPS TO CARE FOR THE CORNEA
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
US6585987B1 (en) 1998-11-13 2003-07-01 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
JP2000159659A (ja) * 1998-11-30 2000-06-13 Kazuo Tsubota 眼科用人工涙液
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
CA2416169C (en) 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
DE60140007D1 (de) 2000-11-08 2009-11-05 Fxs Ventures Llc Verbesserte ophthalmische und kontaktlinsenlösungen mit einfachen sacchariden als konservierungsverbesserer
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
PT1551417E (pt) * 2002-10-18 2008-10-31 Aqueous Pharma Ltd Formulação de lágrimas com três camadas
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
JPWO2004084877A1 (ja) 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
CA2839849C (en) * 2003-06-13 2017-03-07 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
CA2549737A1 (en) * 2003-11-10 2005-05-26 Toray Industries, Inc. Polysaccharide-containing composition and tear film stabilizing ophthalmic solution
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
US20080312194A1 (en) * 2007-02-28 2008-12-18 Ousler Iii George W Methods and compositions for normalizing meibomian gland secretions
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
NO2437762T3 (enExample) * 2009-06-05 2018-01-06
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201316984A (zh) 2011-10-06 2013-05-01 Allergan Inc 治療乾眼病的組合物

Also Published As

Publication number Publication date
HUE057140T2 (hu) 2022-04-28
EP2787969A1 (en) 2014-10-15
RU2014127074A (ru) 2016-02-10
US20130150324A1 (en) 2013-06-13
ES2797650T3 (es) 2020-12-03
KR20140107383A (ko) 2014-09-04
AU2017265181A1 (en) 2017-12-14
ZA201404228B (en) 2015-12-23
JP6142419B2 (ja) 2017-06-07
IL233008A0 (en) 2014-07-31
IN2014CN04809A (enExample) 2015-09-18
US20130197083A1 (en) 2013-08-01
PH12014501296B1 (en) 2023-04-05
BR112014013820A8 (pt) 2017-06-13
EP3981387A1 (en) 2022-04-13
AR089123A1 (es) 2014-07-30
WO2013086449A1 (en) 2013-06-13
WO2013086438A1 (en) 2013-06-13
DK2787969T3 (da) 2021-11-01
CL2014001518A1 (es) 2014-10-24
EP4403220A3 (en) 2024-10-23
RU2018119362A (ru) 2018-11-08
EP3666257A1 (en) 2020-06-17
KR102017922B1 (ko) 2019-09-03
SI2787968T1 (sl) 2020-08-31
CA2858574A1 (en) 2013-06-13
RU2018119362A3 (enExample) 2021-09-07
CN108969482A (zh) 2018-12-11
AU2017265181B2 (en) 2019-06-20
JP2015504860A (ja) 2015-02-16
PT2787969T (pt) 2021-11-09
PH12014501296A1 (en) 2014-10-08
DK2787968T3 (da) 2020-06-02
HK1203057A1 (en) 2015-10-16
US9314528B2 (en) 2016-04-19
MY173378A (en) 2020-01-21
PT2787968T (pt) 2020-06-16
EP2787968A1 (en) 2014-10-15
EP2787969B1 (en) 2021-09-29
PL2787969T3 (pl) 2021-12-20
MX2014006804A (es) 2014-09-22
CN104114152A (zh) 2014-10-22
ES2896336T3 (es) 2022-02-24
IL233008A (en) 2017-07-31
SI2787969T1 (sl) 2021-12-31
EP2787968B1 (en) 2020-03-04
EP4403220A2 (en) 2024-07-24
BR112014013820A2 (pt) 2017-06-13
PL2787968T3 (pl) 2020-08-24
CO6990739A2 (es) 2014-07-10
AU2012347459A1 (en) 2014-07-03
HUE049489T2 (hu) 2020-09-28
SG11201403013VA (en) 2014-07-30
CA2858574C (en) 2017-05-30
PH12021553172A1 (en) 2024-05-27
MX355216B (es) 2018-04-10
HK1201458A1 (en) 2015-09-04
TW201325633A (zh) 2013-07-01

Similar Documents

Publication Publication Date Title
US8530449B2 (en) Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
CN102355889B (zh) 基于多不饱和ω-3和ω-6脂肪酸的眼用组合物
US20240293491A1 (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
EP2787968B1 (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
ES3054066T3 (en) Composition for the treatment of dry eye
JP5748385B2 (ja) O/w型エマルション水性点眼剤
JP2024119872A (ja) 長続きする眼の潤滑をもたらす眼用配合物
EP3280395B1 (en) Ophthalmic compositions based on polyunsaturated fatty acids and triacylglycerols
KR20250042756A (ko) 사이클로스포린 에멀젼 및 이의 제조방법
HK40032380A (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
JP6033177B2 (ja) O/w型エマルション水性点眼剤
HK1201458B (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
HK40060657A (en) Ophthalmic formulations providing durable ocular lubrication
HK1166714B (en) Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees